These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23919898)

  • 1. The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.
    Hatta K; Takebayashi H; Sudo Y; Katayama S; Kasuya M; Shirai Y; Morikawa F; Nakase R; Nakamura M; Ito S; Kuga H; Nakamura M; Ohnuma T; Usui C; Nakamura H; Hirata T; Sawa Y;
    Psychiatry Res; 2013 Dec; 210(2):396-401. PubMed ID: 23919898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.
    Walther S; Moggi F; Horn H; Moskvitin K; Abderhalden C; Maier N; Strik W; Müller TJ
    J Clin Psychopharmacol; 2014 Feb; 34(1):124-8. PubMed ID: 24346752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.
    Sakurai H; Suzuki T; Bies RR; Pollock BG; Mimura M; Kapur S; Uchida H
    J Clin Psychiatry; 2016 Oct; 77(10):1381-1390. PubMed ID: 27788310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
    Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
    Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia.
    Hatta K; Sato K; Hamakawa H; Takebayashi H; Kimura N; Ochi S; Sudo Y; Asukai N; Nakamura H; Usui C; Kawabata T; Hirata T; Sawa Y
    Schizophr Res; 2009 Aug; 113(1):49-55. PubMed ID: 19553086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.
    Ganguli R; Brar JS; Mahmoud R; Berry SA; Pandina GJ
    BMC Med; 2008 Jun; 6():17. PubMed ID: 18590519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.
    Ciudad A; Olivares JM; Bousoño M; Gómez JC; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1515-22. PubMed ID: 16820255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia.
    Hatta K; Otachi T; Sudo Y; Hayakawa T; Ashizawa Y; Takebayashi H; Hayashi N; Hamakawa H; Ito S; Nakase R; Usui C; Nakamura H; Hirata T; Sawa Y;
    Schizophr Res; 2011 May; 128(1-3):127-35. PubMed ID: 21420283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
    Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
    Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.
    Alvarez E; Ciudad A; Olivares JM; Bousoño M; Gómez JC
    J Clin Psychopharmacol; 2006 Jun; 26(3):238-49. PubMed ID: 16702888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.
    Jensen JB; Kumra S; Leitten W; Oberstar J; Anjum A; White T; Wozniak J; Lee SS; Schulz SC
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):317-26. PubMed ID: 18759641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
    Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
    Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.
    Skogh E; Sjödin I; Josefsson M; Dahl ML
    J Clin Psychopharmacol; 2011 Feb; 31(1):4-9. PubMed ID: 21192135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.
    Kinon BJ; Volavka J; Stauffer V; Edwards SE; Liu-Seifert H; Chen L; Adams DH; Lindenmayer JP; McEvoy JP; Buckley PF; Lieberman JA; Meltzer HY; Wilson DR; Citrome L
    J Clin Psychopharmacol; 2008 Aug; 28(4):392-400. PubMed ID: 18626265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.
    Faries DE; Ascher-Svanum H; Nyhuis AW; Kinon BJ
    Curr Med Res Opin; 2008 May; 24(5):1399-405. PubMed ID: 18397549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.